Detailed performance report for WATERS CORPORATION covering Q4 2025. Gain clarity on earnings, revenue trends, and AI-enhanced strategic analysis.
Summary of Financial Performance: Waters Corporation reported strong financial results for the fourth quarter of 2025, with a 7% increase in sales on a reported basis and 6% in constant currency. Adjusted EPS grew in the low double digits to $4.53, while GAAP EPS was $3.77. For the full year, sales grew 7%, driven by high single-digit growth in pharma and industrial markets, and recurring revenue increased by 9%. Instrument revenue grew by 5%, led by LC-MS, which consistently achieved high single-digit growth each quarter.
Company Outlook & Strategy: The company completed the acquisition of BD's Biosciences and Diagnostic Solutions business, marking a transformative step to unite expertise across chemistry, physics, and biology. Waters aims for a sustainable, high single-digit growth trajectory, leveraging instrument replacement cycles and innovations like subscription models for Empower. For 2026, Waters expects organic constant currency revenue growth of 5.5% to 7% and anticipates the acquired businesses to contribute $3 billion in revenue.
Key Industry Trends: Waters highlighted strong growth in areas such as GLP-1 testing, PFAS testing, and India generics. Demand for PFAS testing increased due to evolving regulatory landscapes. The company is also positioned well in diagnostics with LC-MS solutions expanding into new analyte categories.
Operational Highlights: Waters transitioned to a subscription-based model for Empower, enhancing long-term recurring revenue. The acquisition of BD's Biosciences and Diagnostic Solutions is expected to drive operational efficiencies and cost synergies. Innovation continued with new product launches like Xevo CDMS for mega molecule characterization.
Challenges & Risks: The company faces challenges from weakened demand in China due to reduced diagnostics testing consumption and U.S. government shutdown impacts on export approvals. A milder flu season also affected point-of-care business performance.
Key Analyst Questions & Responses: Analysts were concerned about the performance of BD's acquired businesses and their path to recovery, especially in lagging areas like U.S. academic/government sectors and early-stage research in China. Waters' management emphasized operational improvements, new product launches, and synergy capture as paths to recovery. Additionally, questions about the impact of transitioning Empower to a subscription model were addressed by highlighting its strategic value despite short-term headwinds on instrument sales growth.
Access the official earnings call transcript for WATERS-CORPORATION 2025 Q4. It provides valuable insights into management commentary, performance drivers, and forward-looking guidance directly from the company.